Standard BioTools Inc.

NASDAQ:LAB

Medical - Devices

Healthcare
$0.57 +3.38%

+$0.03 today

Market cap
$225.03M
Beta
1.38
P/E (TTM)
-3.5
EPS (TTM)
-$0.24
52W Low $0.79High $1.72

Volume 0.70M

Average 2.91M

LAB Interest Expense

Cost of servicing the company's debt during the period.

Standard BioTools Inc.NASDAQ: LAB

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $0, compared with $2K a year earlier. Trailing-twelve-month interest expense was $24K. Over 3 fiscal years it compounded at -81.8% a year.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025, down 1.9 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $6K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0-100.0% QoQ
Last fiscal yearDec 2025
$26K-99.2% YoY
LTMMar 2026
$24K-97.2% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-99.2%——
3-year CAGR-81.8%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
26K USD
Year-over-year change
-99.2%
4-year CAGR
-71.3%

Interest Expense vs competitors

How LAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -97.2% is the lowest of 9, against a peer median of +4.9%.
  • Interest expense amounts to 0.0% of revenue for LAB, versus a peer median of 2.7%.
LAB Competitors
Interest Expense for LAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ADCTADC Therapeutics S.A.LTM Mar 2026$51.75M USD+3.6%+12.0%65.4%
VREXVarex Imaging CorporationLTM Apr 2026$42.1M USD+23.8%-4.7%4.9%
BVSBioventus Inc.LTM Mar 2026$23.3M USD-35.2%+30.1%4.0%
AVNSAvanos Medical, Inc.LTM Mar 2026$7.2M USD-35.7%-26.3%1.0%
KIDSOrthoPediatrics Corp.LTM Mar 2026$6.97M USD+124.2%+35.2%2.9%
TMCITreace Medical Concepts, Inc.LTM Mar 2026$5.58M USD+6.3%+6.5%2.7%
CTKBCytek Biosciences, Inc.LTM Mar 2026$1.9M USD+248.3%-43.1%0.9%
CBLLCeriBell, Inc.LTM Mar 2026$985K USD-50.3%+5.6%1.0%
LABStandard BioTools Inc.LTM Mar 2026$24K USD-97.2%-81.8%0.0%
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$0 USD———
SYSo-Young International Inc.LTM Mar 2026CN¥0 CNY——0.0%
Peer median (excluding LAB) —+4.9%+6.1%2.7%

Competitors are the stored peer set for LAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue130.58M97.95M106.34M174.43M85.33M
Cost of Revenue61.21M60.9M55.89M90.17M42.79M
Gross Profit69.37M37.05M50.45M84.26M42.54M
Gross Margin53.1%37.8%47.4%48.3%49.9%
Research & Development37.94M37.38M25.95M62.41M25.99M
Selling, General & Admin98.89M102.29M87.54M156.61M109.86M
Operating Expenses136.83M153.26M127.05M259.5M135.85M
Depreciation & Amortization15.57M15.03M15.18M16.86M6.98M
EBITDA(44.27M)(173.57M)(54.46M)(118.14M)(89.69M)
EBITDA Margin-33.9%-177.2%-51.2%-67.7%-105.1%
Operating Income(67.46M)(116.21M)(76.6M)(175.24M)(93.31M)
Operating Margin-51.7%-118.6%-72.0%-100.5%-109.3%
Interest Income02.23M5.57M20.2M9.18M
Interest Expense3.82M4.33M4.57M3.32M26K
Other Income / Expenses3.8M(76.72M)2.4M36.92M(3.4M)
Income Before Tax(63.66M)(192.93M)(74.2M)(138.31M)(96.7M)
Pre-Tax Margin-48.8%-197.0%-69.8%-79.3%-113.3%
Income Tax Expense(4.42M)(2.83M)452K573K(37.88M)
Net Income(59.24M)(190.1M)(74.66M)(138.89M)(74.9M)
Net Margin-45.4%-194.1%-70.2%-79.6%-87.8%
EPS (Basic)(0.78)(2.43)(0.94)(0.52)(0.20)
EPS (Diluted)(0.78)(2.43)(0.94)(0.52)(0.20)
Weighted Avg Shares75.79M78.31M79.16M352.67M381.62M
Weighted Avg Shares (Diluted)75.79M78.31M79.16M352.67M381.62M

Standard BioTools Inc.

NASDAQ:LAB

Intrinsic Alpha fair value

Locked

Current Price

$0.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.